Mapp Biopharmaceutical & Gilead Sciences
3 shared events · Importance 3 · Last updated Jul 10, 2026
Mapp Biopharmaceutical is a trial partner with Gilead Sciences, contributing its experimental drug MBP134 to a clinical study for Bundibugyo ebolavirus alongside Gilead's remdesivir.
Track how Mapp Biopharmaceutical and Gilead Sciences interact across events, view sentiment trends, and discover connected entities.
Open Dashboard